GSK partners with Oxford Bio for cancer Abs in $370M deal
UK drug major GlaxoSmithKline has taken further steps to bolster its early-stage oncology pipeline by forming a strategic alliance with Oxford BioTherapeutics to discover, develop and commercialize novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer.
Under the alliance, GSK will develop novel antibody therapies against selected Oxford Bio targets. In parallel, the latter will develop one of its own monoclonal antibodies through to clinical proof-of-concept, at which point GSK will have an exclusive option to in-license this and will thereafter assume responsibility for further clinical development and commercialization on a worldwide basis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze